The Nucleic Acid Core Facility is located in the Department of Gastrointestinal Oncology and Digestive Diseases in a 500 feet/2 laboratory. The Facility was created in the fall of 1996 through a CCSG supplement in Human Cancer Genetics. The NACF is a centralized facility for extraction of high-quality DNA from peripheral blood leukocytes and cell lines by using an Applied Biosystems Model 341 Nucleic Acid Extractor. This allows for the rapid isolation of highly purified, high- molecular-weight DNA. M.D. Anderson Cancer Center has a wealth of patient and family resources for studies of cancer-susceptibility genes. Most DNA isolation techniques used by individual laboratories required significant technical support and take 3 or more days. A centralized automated facility capable of producing PCR-grade DNA overnight from peripheral blood or cell is a major improvement in efficiency. The facility will be expanded to provide PCR-based genetic testing of transgenic animals. Because the high degree of product purity provided by the Model 341 Nucleic Acid Extractor will not be necessary for this testing, a more crude but rapid extraction procedure will be used to isolate DNA from mouse tails. The DNA will be subjected to PCR by using primates specifically designed to detect the transgenes, and animals positive for the transgenes will be identified. A large number of transgenic animal lines from over 20 different laboratories at M.D. Anderson are currently under investigation. Conducting DNA extraction from transgenic animal tails and PCR-based genetic testing in one centralized facility will be more efficient than performing these tasks in individual laboratories, as it will allow automation of each step by the use of Beckman Biomek 2000 robotic arms and multiplex PCR.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-24S2
Application #
6217269
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
24
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Murray, Thomas A; Yuan, Ying; Thall, Peter F et al. (2018) A utility-based design for randomized comparative trials with ordinal outcomes and prognostic subgroups. Biometrics 74:1095-1103
Sun, Lin-Lin; Yang, Ri-Yao; Li, Chia-Wei et al. (2018) Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J Cancer Res 8:1307-1316
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Veletic, Ivo; Manshouri, Taghi; Newberry, Kate J et al. (2018) Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis. Br J Haematol :
El Fakih, Riad; Jabbour, Elias; Ravandi, Farhad et al. (2018) Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults. Am J Hematol 93:286-295
Sankhala, Kamalesh; Takimoto, Chris H; Mita, Alain C et al. (2018) Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules. Invest New Drugs :
Shen, Weining; Ning, Jing; Yuan, Ying et al. (2018) Model-free scoring system for risk prediction with application to hepatocellular carcinoma study. Biometrics 74:239-248
Wu, Shaofang; Wang, Shuzhen; Gao, Feng et al. (2018) Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma. Neuro Oncol 20:78-91
Romano, Gabriele; Chen, Pei-Ling; Song, Ping et al. (2018) A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov 8:556-567
Dray, Beth K; Raveendran, Muthuswamy; Harris, R Alan et al. (2018) Mismatch repair gene mutations lead to lynch syndrome colorectal cancer in rhesus macaques. Genes Cancer 9:142-152

Showing the most recent 10 out of 12418 publications